Literature DB >> 10597197

In vivo assessment of vascular endothelial growth factor-induced angiogenesis.

M Lewin1, S Bredow, N Sergeyev, E Marecos, A Bogdanov, R Weissleder.   

Abstract

To determine whether vascular endothelial growth factor (VEGF)-induced tumor microvascularity is detectable by in vivo NMR imaging, an experimental study was conducted in nude mice. Human breast cancer cells (MCF-7) and MCF-7 cells stably transfected with the cDNA for the VEGF165 isoform (MV165) were grown in nude mice and models were characterized by RT-PCR, Western blotting, ELISA, immunohistochemistry and NMR imaging using a novel synthetic protected graft copolymer (PGC) as a vascular probe. MV165 tumors showed a 1.6-fold higher microvascular density by histology. Both tumors showed identical MR signal intensities on non-contrast and Gd-DTPA enhanced images. PGC enhanced MR imaging of tumoral vascular volume fraction (VVF), however, revealed significant differences between the 2 tumor types (MV165: 8.9 +/- 2.1; MCF-7: 1.7 +/- 0.5; p < 0.003), as expected from histology. VVF changes were more heterogeneous in the MV165 model both among tumors as well as within tumors as determined 3-dimensionally at submillimeter resolutions. Our results have potential applications for non-invasive assessment of angiogenesis by in vivo imaging and for clinical monitoring during angiogenic therapies.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10597197     DOI: 10.1002/(sici)1097-0215(19991210)83:6<798::aid-ijc16>3.0.co;2-w

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  14 in total

1.  Imaging the pancreatic vasculature in diabetes models.

Authors:  Zdravka Medarova; Dale L Greiner; Marytheresa Ifediba; Guangping Dai; Elijah Bolotin; Gerardo Castillo; Alexei Bogdanov; Mohanraja Kumar; Anna Moore
Journal:  Diabetes Metab Res Rev       Date:  2011-11       Impact factor: 4.876

2.  Molecular MR Imaging Probes.

Authors:  Umar Mahmood; Lee Josephson
Journal:  Proc IEEE Inst Electr Electron Eng       Date:  2005-04       Impact factor: 10.961

3.  Reduction of tumorigenicity of SMMC-7721 hepatoma cells by vascular endothelial growth factor antisense gene therapy.

Authors:  Y C Tang; Y Li; G X Qian
Journal:  World J Gastroenterol       Date:  2001-02       Impact factor: 5.742

4.  Vascularization in tissue engineering: fundamentals and state-of-art.

Authors:  Guang Yang; Bhushan Mahadik; Ji Young Choi; John P Fisher
Journal:  Prog Biomed Eng (Bristol)       Date:  2020-01-09

5.  Visualizing the acute effects of vascular-targeted therapy in vivo using intravital microscopy and magnetic resonance imaging: correlation with endothelial apoptosis, cytokine induction, and treatment outcome.

Authors:  Mukund Seshadri; Joseph A Spernyak; Patricia G Maiery; Richard T Cheney; Richard Mazurchuk; David A Bellnier
Journal:  Neoplasia       Date:  2007-02       Impact factor: 5.715

6.  Effects of hormone deprivation and 2-methoxyestradiol combination therapy on hormone-dependent prostate cancer in vivo.

Authors:  Fuminori Sato; Hiroshi Fukuhara; James P Basilion
Journal:  Neoplasia       Date:  2005-09       Impact factor: 5.715

Review 7.  'In vivo' optical approaches to angiogenesis imaging.

Authors:  T J A Snoeks; C W G M Löwik; E L Kaijzel
Journal:  Angiogenesis       Date:  2010-05-08       Impact factor: 9.596

8.  In vitro and In vivo imaging of antivasculogenesis induced by Noggin protein expression in human venous endothelial cells.

Authors:  Hye-Won Kang; Ronn Walvick; Alexei Bogdanov
Journal:  FASEB J       Date:  2009-08-19       Impact factor: 5.191

9.  Protected Graft Copolymer (PGC) in Imaging and Therapy: A Platform for the Delivery of Covalently and Non-Covalently Bound Drugs.

Authors:  Alexei A Bogdanov; Mary Mazzanti; Gerardo Castillo; Elijah Bolotin
Journal:  Theranostics       Date:  2012-06-04       Impact factor: 11.556

Review 10.  Application of magnetic resonance imaging to angiogenesis in breast cancer.

Authors:  M O Leach
Journal:  Breast Cancer Res       Date:  2001       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.